Heartland Advisors Inc. boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 11.5% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 129,740 shares of the medical instruments supplier’s stock after purchasing an additional 13,396 shares during the period. Heartland Advisors Inc.’s holdings in Becton, Dickinson and Company were worth $19,634,000 as of its most recent filing with the SEC.
Other large investors have also added to or reduced their stakes in the company. Auto Owners Insurance Co raised its holdings in shares of Becton, Dickinson and Company by 22,225.2% in the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock worth $790,079,000 after purchasing an additional 40,528,680 shares during the period. Vanguard Group Inc. grew its holdings in Becton, Dickinson and Company by 13.0% during the fourth quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock valued at $7,118,282,000 after purchasing an additional 4,223,149 shares during the period. BlackRock Inc. purchased a new stake in Becton, Dickinson and Company in the second quarter worth $3,721,533,000. State Street Corp raised its stake in shares of Becton, Dickinson and Company by 0.8% in the fourth quarter. State Street Corp now owns 13,989,132 shares of the medical instruments supplier’s stock valued at $2,714,871,000 after buying an additional 116,737 shares during the period. Finally, First Eagle Investment Management LLC raised its stake in shares of Becton, Dickinson and Company by 16.5% in the fourth quarter. First Eagle Investment Management LLC now owns 11,646,000 shares of the medical instruments supplier’s stock valued at $2,260,139,000 after buying an additional 1,651,592 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.
Analyst Ratings Changes
Several research analysts have recently weighed in on BDX shares. The Goldman Sachs Group cut their price target on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research note on Wednesday, May 27th. Stifel Nicolaus set a $195.00 price objective on shares of Becton, Dickinson and Company in a report on Friday, August 7th. Barclays increased their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Royal Bank Of Canada lifted their target price on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a research note on Thursday, August 13th. Finally, TD Cowen upped their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $185.67.
Becton, Dickinson and Company Trading Up 2.3%
Shares of BDX opened at $191.95 on Friday. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $192.30. The stock has a market cap of $52.89 billion, a PE ratio of 57.82, a P/E/G ratio of 13.22 and a beta of 0.19. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The business’s 50-day moving average price is $161.58 and its 200-day moving average price is $161.13.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. Becton, Dickinson and Company’s revenue for the quarter was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. On average, equities analysts forecast that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.
Becton, Dickinson and Company Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is 126.51%.
Insider Transactions at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. This represents a 7.71% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. The trade was a 3.63% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 11,779 shares of company stock valued at $1,974,669. 0.40% of the stock is currently owned by company insiders.
About Becton, Dickinson and Company
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Articles
- Five stocks we like better than Becton, Dickinson and Company
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
